Skip to main content
. 2017 Oct 30;15:193. doi: 10.1186/s12916-017-0954-x

Fig. 1.

Fig. 1

Flow diagram of the selection of trials for second-line treatments in advanced NSCLC with wild-type or unknown status for EGFR. ° Details in Appendix 6; * Additional articles not identified by searching bibliographic databases; $ 5 trials (10 reports) with chemotherapy (i.e., docetaxel or pemetrexed) at the investigators’ discretion. The last search for randomized trials was conducted on June 6, 2017